Download Files:

Ramatroban

$42$385

Products Details

Product Description

– Ramatroban is a selective thromboxane A2 (TxA2, IC50=14 nM) antagonist, which also antagonizes CRTH2 (IC50=113 nM) by inhibiting PGD2 binding.

Web ID

– HY-B0745

Storage Temperature

– -20°C, 3 years; 4°C, 2 years (Powder)

Shipping

– Room Temperature

Applications

– COVID-19-immunoregulation

Molecular Formula

– C21H21FN2O4S

References

– [1]Sugimoto H, et al. An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D<sub>2</sub>-induced eosinophil migration in vitro. J Pharmacol Exp Ther. 2003 Apr;305(1):347-52.|[2]Haba R, et al. Central CRTH2, a second prostaglandin D<sub>2</sub> receptor, mediates emotional impairment in the lipopolysaccharide and tumor-induced sickness behavior model. J Neurosci. 2014 Feb 12;34(7):2514-23.|[3]Stearns BA, et al. Novel tricyclic antagonists of the prostaglandin D<sub>2</sub> receptor DP2 with efficacy in a murine modelof allergic rhinitis. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4647-51.

CAS Number

– 116649-85-5

Molecular Weight

– 416.47

Compound Purity

– 99.10

SMILES

– O=C(O)CCN1C2=C(C3=C1C=CC=C3)C[C@H](NS(=O)(C4=CC=C(F)C=C4)=O)CC2

Clinical Information

– Launched

Research Area

– Inflammation/Immunology; Endocrinology; Cancer

Solubility

– DMSO : 125 mg/mL (ultrasonic)

Target

– Prostaglandin Receptor

Isoform

– DP;TXA2/TP

Pathway

– GPCR/G Protein

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.